* Sanofi and Regeneron announce dupilumab biologics
license application accepted for priority review by U.S. FDA
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
The post BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA appeared first on NASDAQ.